Return to Listing

8 result(s) for Melanoma

PI Name Protocol # Title
Sancy Leachman IRB00010561 War on Melanoma: Enlisting a cohort of melanoma survivors and their families
Prakash Ambady STUDY00016046 Response Assessment to Pembrolizumab with Standard of Care Therapy in Oligometastatic Brain Tumors from Melanoma, and Glioblastoma Using Ferumoxytol Steady State Imaging– A Pilot Study
John Vetto STUDY00017104 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study
Rajan Kulkarni STUDY00017648 VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
Matthew Taylor STUDY00018687 A Phase 3, Randomized, Open-label Study of NKTR-214 combined with Nivolumab Versus Nivolumab in Participants with Previously untreated Unresectable or Metastatic Melanoma
Dale Han STUDY00019285 A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Matthew Taylor STUDY00019679 ADJUVANT THERAPY WITH PEMBROLIZUMAB VERSUS PLACEBO IN RESECTED HIGHRISK STAGE II MELANOMA: A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY (KEYNOTE 716)
Matthew Taylor STUDY00019746 A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080